Back

SELECT in the light of FAST-MI. Potential population-based benefit of semaglutide 2.4mg/week on mortality, an extrapolation from the SELECT trial results to the FAST-MI registries.

31 August 2026 (08:27 - 08:39)
Organised by: Logo
Congress Presentation Part of: Secondary prevention strategies in coronary artery disease Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Francois Schiele

Regional University Hospital Jean Minjoz, Besancon (France)

4 More presentations in this session

Presentation thumbnail
Time-to-benefit of glucagon-like peptide-1 receptor agonists for cardiovascular protection in type 2 diabetes
Miss C. Chang (New Taipei, TW)
Abstract
Presentation thumbnail
Beta-blocker therapy and all-cause mortality after percutaneous coronary intervention: a state-wide propensity score matched analysis stratified by left ventricular ejection fraction
Mrs P. Cataldo Miranda (Melbourne, AU)
Abstract
Presentation thumbnail
Distinct phenotype of very early-onset coronary artery disease (≤35 years): baseline findings from a multicentre prospective cohort
Miss X. Ding (Beijing, CN)
Abstract
Presentation thumbnail
Beyond the genome: the dominant role of biological age over polygenic risk in post-PCI mortality prediction.
Miss M. Liu (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Secondary prevention strategies in coronary artery disease

The Event

Event poster

ESC Congress 2026

31 August 2026 08:27 CET
You may be interested in
thumbnail
Congress Presentation
Prevalence of SELECT-eligibility and incidence of 5-year major adverse cardiovascular outcomes in non-diabetic patients with myocardial infarction
27 August 2023
thumbnail
Congress Presentation
European differences in characteristics, treatments and outcomes in patients with non-ST-elevation myocardial infarction -novel insights from four national real-world registries
30 August 2020
thumbnail
Congress Presentation
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
1 September 2025
thumbnail
Congress Presentation
Direct oral anticoagulants, all-cause mortality and cardiovascular events in patients with atrial fibrillation with and without obesity: a sub-analysis of the nationwide START registry.
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources